Recepta Biopharma   Report issue

For profit Phase 2
Founded: Sao Paulo Brazil (2006)
Status: Left NME R&D (2018)

Organization Overview

First Clinical Trial
2008
NCT00617773
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Alternative names

Recepta Biopharma S.A.

Active Ingredients

Drugs in Phase 2 Trials (2)

hu3s193 (2 trials)

y90 monoclonal antibody hu3s193 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Fallopian Tube Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2